• In early August 2026, BioMarin Pharmaceutical reported second-quarter revenue of US$989.71 million, raised its full-year 2026 revenue guidance range, and issued stronger second-half outlook commentary supported by Amicus integration and continued patient growth across its portfolio.
• Despite higher revenue, net income and earnings per share fell sharply year-on-year, highlighting the trade-off between accelerated growth investments, acquisition-related costs, and profitability at a time when the company is also putting a US$719.24 million shelf registration in place for an ESOP-related stock offering.
• We’ll now examine how BioMarin’s raised 2026 revenue guidance and stronger Voxzogo performance affect its existing investment narrative and risk balance.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

BioMarin Pharmaceutical Investment Narrative Recap

To own BioMarin today, you have to be comfortable with a rare disease story that is still heavily centered on Voxzogo and now the Amicus integration, while accepting near term earnings pressure from higher R&D, SG&A and deal costs. The latest guidance raise and stronger Voxzogo trends support the revenue side of that thesis, but the sharp drop in net income underlines that margin compression and spending discipline remain the key short term swing factors, rather than a new single catalyst.

The most relevant recent development here is BioMarin’s updated 2026 revenue guidance to US$3,875 million to US$3,925 million, paired with commentary that Q4 should account for well over half of second half sales. That outlook ties directly into the existing catalyst of portfolio expansion and patient growth, but also reinforces an existing risk: dependence on uneven ordering in a few markets that can make quarterly results and earnings trajectory harder to read.

Yet behind the stronger 2026 outlook, investors should still be aware of how rising R&D, integration costs and pricing pressure could combine to...

BioMarin Pharmaceutical's narrative projects $4.9 billion revenue and $1.3 billion earnings by 2029. This requires 14.8% yearly revenue growth and a $1.0 billion earnings increase from $268.7 million.

Uncover how BioMarin Pharmaceutical's forecasts yield a $87.85 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming revenue of about US$4.5 billion and earnings of roughly US$753 million by 2029, and they focus much more on pricing and concentration risks than on the current guidance boost, so if you are comparing views you will see how sharply opinions can diverge and why this new guidance could shift those expectations in different ways.

Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.